Glucantime fever with parenteral meglumine antimonate in patients of cutaneous leishmaniasis.
作者信息
Rashid Brigadier Nasser, Tabassum Sadia, Ullah Rao Major Sibghat, Masood Sadia, Abbas Major Muhammad, Mumtaz Major Jauhar
出版信息
J Coll Physicians Surg Pak. 2010 Jul;20(7):496.
PMID:20642959
Abstract
摘要
相似文献
1
Glucantime fever with parenteral meglumine antimonate in patients of cutaneous leishmaniasis.
J Coll Physicians Surg Pak. 2010 Jul;20(7):496.
2
Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
Pathol Biol (Paris). 1997 Jun;45(6):496-9.
3
[N-methyl glucamine antimoniate or Glucantime].
Med Trop (Mars). 2000;60(4):342-3.
4
Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Am J Trop Med Hyg. 2005 Feb;72(2):133-7.
5
Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala.
Am J Trop Med Hyg. 1990 Jan;42(1):43-50. doi: 10.4269/ajtmh.1990.42.43.
6
Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
Clin Infect Dis. 1993 May;16(5):730-1. doi: 10.1093/clind/16.5.730.
7
Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey.
J Parasitol. 2004 Aug;90(4):853-9. doi: 10.1645/GE-185R.
8
Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
Am J Trop Med Hyg. 2005 Apr;72(4):421-2.
9
[Glucantime reaction with fatal outcome following treatment of cutaneous leishmaniasis].
Ann Dermatol Venereol. 2008 Apr;135(4):317-8. doi: 10.1016/j.annder.2007.10.003. Epub 2008 Mar 20.
10
[Glucantime injection: benefit versus toxicity].
Med Mal Infect. 2005 Jan;35(1):42-5. doi: 10.1016/j.medmal.2004.07.032.
Zotero 插件